Related Experiment Videos
Bacteremia caused by Arcobacter cryaerophilus 1B
P R Hsueh1, L J Teng, P C Yang
1Department of Laboratory Medicine, National Taiwan University Hospital, and School of Medical Technology, Taipei.
Journal of Clinical Microbiology
|February 1, 1997
Summary
Arcobacter cryaerophilus group 1B, a pathogen typically found in animals, was identified in a uremic patient with pneumonia. Successful treatment involved ceftizoxime and tobramycin, indicating effective therapeutic options.
Area of Science:
- Microbiology
- Infectious Diseases
- Clinical Medicine
Background:
- Arcobacter cryaerophilus group 1B is a gram-negative, curved bacillus.
- This bacterium is primarily recognized as a pathogen in bovine and porcine species.
- Uremic patients present with compromised immune systems, increasing susceptibility to infections.
Observation:
- Arcobacter cryaerophilus group 1B was isolated from the bloodstream of a patient experiencing hematogenous pneumonia.
- The patient had underlying uremia, a condition characterized by kidney dysfunction.
Findings:
- The causative agent of the pneumonia and bacteremia was identified as Arcobacter cryaerophilus group 1B.
- The patient's infection was successfully treated with a combination of ceftizoxime and tobramycin.
Implications:
- This case highlights the potential for Arcobacter cryaerophilus group 1B to cause severe human infections, particularly in immunocompromised individuals.
- Ceftizoxime and tobramycin demonstrate efficacy in treating Arcobacter cryaerophilus group 1B infections.
- Further research is warranted to understand the epidemiology and clinical spectrum of Arcobacter infections in humans.